All News
Filter News
Found 809,042 articles
-
Nimbus Therapeutics Publishes Structural Analysis Highlighting Mechanisms for Selective Inhibition of CTPS1
9/30/2021
Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today published research in the Proceedings of the National Academy of Sciences describing the structural basis for isoform-specific inhibition of human CTPS1 (CTP synthase 1).
-
Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck
9/30/2021
Sutro Biopharma, Inc. today announced that Merck has extended the research term for the first cytokine derivative program under the 2018 Merck Agreement, for an additional two years.
-
GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates
9/30/2021
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed a license agreement with Dutch biotech ProteoNic B.V. for the use of its premium 2G UnicTM technology platform to enable high-yield production of GigaGen’s mono- and polyclonal antibody drug candidates.
-
IMPACT Therapeutics Appoints Dr. Chun-Pyn Shen as Head of Regulatory Affairs
9/30/2021
IMPACT Therapeutics announced that Dr. Chun-Pyn Shen was appointed as Head of Regulatory Affairs (Vice President).
-
AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance
9/30/2021
AngioDynamics, Inc. today announced financial results for the first quarter of fiscal year 2022, which ended August 31, 2021.
-
Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS
9/30/2021
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that it has received a positive decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the U.S. Food and Drug Administration’s (FDA) approval of another amifampridine product, Ruzurgi®
-
Carbon Health Unveils Carbon for Research, a Clinical Trial Research Program to Drive Healthcare Advancements
9/30/2021
Carbon Health, a leading national healthcare provider, today unveiled Carbon for Research, a clinical trial research program that has been partnering with therapeutics companies to conduct cutting-edge research for clinical trials focused on medical devices, diagnostics, therapeutics and vaccines.
-
Love Pharma, Inc., Formerly Glenbriar Technologies, Inc., Announces Name Change, Consolidation, and Acquisition of Kick Pharmaceuticals, Inc
9/30/2021
Love Pharma Inc. announces that it has changed its name, has completed the arms-length acquisition of all of the shares of private BC-based Kick Pharmaceuticals, Inc.
-
Purolite announces the commercialization of two novel affinity chromatography resins designed to address the diversity in today's biomolecule pipelines of antibodies, vaccines and gene therapy
9/30/2021
Purolite, a global manufacturer of resin-based chromatography separation, purification and extraction technologies, announced today the commercialization of two novel next-generation chromatography resins:
-
Electromedical Technologies Receives Key Medical Device Certification
9/30/2021
Electromedical Technologies, Inc . is pleased to announce that it has passed the ISO 13485:2016 recertification audit for Medical Device and Quality Management Systems.
-
Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of isavuconazole in Japan
9/30/2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) has filed a New Drug Application (NDA) for the marketing authorization of isavuconazole (Cresemba ® ) in Japan for the treatment of the fungal infections aspergillosis, mucormycosis and cryptococcosis.
-
Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting
9/30/2021
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that detailed data from the Phase 3 DERBY and OAKS studies were presented for the first time as part of two oral presentations at the Retina Society Annual Scientific Meeting in Chicago.
-
Targovax ASA appoints Ola Melin as Head of Manufacturing
9/30/2021
Targovax ASA announces the appointment of Ola Melin as Head of Manufacturing. He will take a leading role in driving Targovax's Chemistry, Manufacturing, and Controls program forward.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 30, 2021
9/30/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 43 individuals hired by Sarepta in September 2021.
-
AB Science today reports its revenues for the first half of 2021 and provides an update on its activities
9/30/2021
AB Science SA reports its revenues for the first half of 2021 and provides an update on its activities.
-
American Lung Association Announces 24 COVID-19 Studies; Focus on 'Long COVID'
9/30/2021
As the nation's trusted champion of lung health, the American Lung Association announced it is supporting 24 COVID-19 research studies, including a few with National Heart, Lung, and Blood Institute to determine susceptibility and treatment for 'long COVID.' This research commitment is part of the organization's ongoing three-year $25 million COVID-19 Action Initiative.
-
Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration
9/30/2021
Sunovion Pharmaceuticals Inc.,its parent company Sumitomo Dainippon Pharma Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront, non-racemic ratio of amisulpride enantiomers, SEP-378614 and SEP-380135.
-
Sensorion to Attend Three Conferences in October 2021, Including the Cell & Gene Meeting on the Mesa
9/30/2021
Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announce the participation of members of the company’s senior management in three investor and scientific conferences during October 2021.
-
Cynata Enters into a New Strategic Partnership with Fujifilm
9/30/2021
Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced that it has entered into a new strategic partnership agreement with Fujifilm Corporation.
-
PAVmed to Host Digital Health Virtual Investor Event
9/30/2021
PAVmed Inc. announced that on October 26, 2021, from 1 to 3 PM EDT, it will host a virtual investor event focused on its digital health subsidiary Veris Health entitled Veris Heath: Bringing Digital Health to Cancer Care.